As Yuhan Corporation dashes for the National Health Insurance (NHI) reimbursement talk on Leclaza (lazertinib), affected multinational pharmaceutical companies are tensing up.

A Korean-made new drug Leclaza is to get reviewed by the Cancer Deliberation Committee in February, the related industry sees that the non-small cell lung cancer (NSCLC) treatment area would face a dynamic change sooner than expected.

Especially, the targeted therapies waiting for reimbursement listing or expansion are closely following the progress of Yuhan’s third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Leclaza.

◆ Cyramza combined with a first-gene

Eo, Yun-Ho(unkindfish@dailypharm.com)